Lumida
/BLFS
⌘K
BioLife Solutions Inc

BioLife Solutions Inc

BLFS
$34.95USD+0.09%+0.03 today

MARKET CAP

1.7B

P/E (TTM)

120.4x

FWD P/E

127.2x

DAY RANGE

$35 – $35

52W RANGE

$18
$38

AI Summary

Stalk
Sell NowMedium

Recent decisive support failure on elevated volume and sliding below the 9EMA and 20EMA has shifted the medium-term bias bearish, despite the intact long-term uptrend. Short-term conditions remain unfavorable for buyers with no reversal patterns, so the preferred execution is to sell into any relief rallies around the broken support-turned-resistance near the 9/20 EMAs.

  • Q2 revenue $28.5 M (+21% YoY) with GAAP net income $45.1 M
  • Adjusted EBITDA $7.4 M (26% margin) and 64% GAAP gross margin
  • Key customers drive majority of sales, raising concentration risk
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$119.2M$76.2M$68.0M$74.6M$96.2M
YoY %+147.8%-36.0%-10.8%+9.7%+28.9%
P / Sales12.0x10.0x10.3x16.0x12.2x
EV / Sales12.1x10.9x11.0x15.5x12.2x
Gross Profit, Adj.$37.0M$46.9M$41.3M$50.1M$62.1M
YoY %+35.0%+26.6%-11.9%+21.2%+24.0%
Margin %31.1%61.5%60.7%67.1%64.6%
EV / Gross Profit38.9x17.6x18.0x23.1x19.0x
EBITDA, Adj.$-17.8M$5.8M$-4.9M$4.2M$-11.9M
YoY %-1762.1%+132.6%-184.7%+185.2%-384.8%
Margin %-14.9%7.6%-7.2%5.6%-12.4%
EV / EBITDA-81.1x142.8x-151.9x276.0x-98.8x
EBIT$-33.5M$-5.9M$-17.2M$-4.5M$-16.6M
YoY %-618.5%+82.3%-190.5%+74.0%-270.8%
Margin %-28.1%-7.8%-25.3%-6.0%-17.3%
EV / EBIT-43.0x-139.7x-43.3x-258.0x-70.9x
Net Income$-8.9M$-139.8M$-68.0M$-20.2M$-4.6M
YoY %-588.9%-1469.4%+51.4%+70.3%+77.2%
Net Margin-7.5%-183.4%-100.0%-27.0%-4.8%
EPS (GAAP)-$0.23-$3.25-$1.55-$0.44-$0.10
YoY %-283.3%-1313.0%+52.3%+71.6%+77.3%